During the past decade, MHAT - Pazardzhik AD conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MHAT - Pazardzhik AD" #1 sponsor was "Daiichi Sankyo, Inc." with 1 trials, followed by "Esperion Therapeutics, Inc." with 1 trials sponsored, "Ineos Healthcare Limited" with 1 trials sponsored, "Kowa Research Institute, Inc." with 1 trials sponsored and "PPM Services S.A." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MHAT - Pazardzhik AD" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "Quintiles, Inc." with 1 trials as a collaborator and "The Cleveland Clinic" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "MHAT - Pazardzhik AD" are "Atrial Fibrillation" (1 trials), "Cardiovascular Diseases" (1 trials), "Chronic Kidney Failure" (1 trials), "Colitis, Ulcerative" (1 trials) and "Dyslipidemia" (1 trials). Many other conditions were trialed in "MHAT - Pazardzhik AD" in a lesser frequency.

Most popular intervention types in "MHAT - Pazardzhik AD" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Adalimumab" (1 trials), "Adalimumab placebo" (1 trials), "Bempedoic acid 180 mg tablet" (1 trials) and "Edoxaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "MHAT - Pazardzhik AD" are 6 trials for "All" genders.

Currently, there are NaN active trials in "MHAT - Pazardzhik AD". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in MHAT - Pazardzhik AD, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in MHAT - Pazardzhik AD, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".